Expert Review of Hematology最新文献_第2页

COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 DOI: 10.1080/17474086.2025.2459260

Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz

{"title":"COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature.","authors":"Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz","doi":"10.1080/17474086.2025.2459260","DOIUrl":"10.1080/17474086.2025.2459260","url":null,"abstract":"Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication whose association with COVID-19 is controversial. Understanding this connection is essential due to its significant impact on patient outcomes, and timely diagnosis and intervention are critical in managing this condition effectively.Areas covered: This paper presents a case of TTP triggered by COVID-19 infection in a 48-year-old female. Additionally, a comprehensive literature review was conducted using PubMed and Google Scholar databases, from inception through August 2024, to identify all published cases of COVID-19-associated TTP. The literature search focused on adult cases of TTP secondary to COVID-19 infection, highlighting the treatments used and patient outcomes.Expert opinion: In this report, we highlight the importance of recognizing TTP as a possible complication of COVID-19. While the standard treatment for TTP - plasma exchange and corticosteroids - remains the primary approach, we note that COVID-19-related cases exhibit a high risk of early relapse, as seen in our patient. The literature review suggests that TTP triggered by COVID-19 may have unique characteristics, such as a persistent low ADAMTS13 activity and increased relapse rates. Larger studies are necessary to develop optimal treatment guidelines and understand whether the presence of COVID-19 alters the typical clinical course of TTP.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-15"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring shared pathogenesis of multiple myeloma and osteoporosis via bioinformatic analysis.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-02-14 DOI: 10.1080/17474086.2025.2465456

Yajie Wang, Chengdi Liu, Kegong Tang, Jiyun Zhang, Xinran Liu, Yiming Ma, Xiaofei Li

{"title":"Exploring shared pathogenesis of multiple myeloma and osteoporosis via bioinformatic analysis.","authors":"Yajie Wang, Chengdi Liu, Kegong Tang, Jiyun Zhang, Xinran Liu, Yiming Ma, Xiaofei Li","doi":"10.1080/17474086.2025.2465456","DOIUrl":"10.1080/17474086.2025.2465456","url":null,"abstract":"Background: The purpose of this study is to explore the common differentially expressed genes (DEGs) between multiple myeloma (MM) and osteoporosis and the associated molecular mechanisms.Research design and methods: We obtained the overlapping DEGs between MM and osteoporosis with the GEO2R online tool. Then, the DEGs were clustered on the MetaCore website to identify the biological process and pathway. In addition, the STRING database and Cytoscape were used to construct the protein-protein interaction (PPI) network and identify hub genes. Finally, miRNA-gene and transcriptional factor (TF)-gene interaction networks were constructed.Results: A total of 252 genes were identified as DEGs in the overlapping two datasets. Functional analysis emphasizes the crucial role of the cell cycle in these two diseases. 10 hub genes were identified using cytoHubba, including CCNA2, ASPM, MKI67, FN1, FEN1, STAT1, DEPDC1, ITGB8, DYNC2LI1, HBEGF. In addition, according to the miRNA-gene and TF-gene interaction networks, part of TFs (RELA, TP53), and miRNAs (miR-26b-5p, miR-192-5p) may be identified as key regulators in MM and osteoporosis at the same time.Conclusions: The present study reveals the common pathogenesis of MM and osteoporosis. These shared pathways may provide new targets for further mechanistic studies of the pathogenesis and treatment of MM and osteoporosis.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"167-176"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17474086.2025.2459251

Mingyi Yang, Yani Su, Pengfei Wen, Jiale Xie, Xianjie Wan, Ke Xu, Wensen Jing, Zhi Yang, Lin Liu, Peng Xu

{"title":"Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study.","authors":"Mingyi Yang, Yani Su, Pengfei Wen, Jiale Xie, Xianjie Wan, Ke Xu, Wensen Jing, Zhi Yang, Lin Liu, Peng Xu","doi":"10.1080/17474086.2025.2459251","DOIUrl":"10.1080/17474086.2025.2459251","url":null,"abstract":"Objective: Deep vein thrombosis (DVT) is a known complication of fractures. This study aimed to explore the genetic causal relationship between DVT and fracture sites.Research design and methods: The exposures analyzed in this study included fracture of femur (FFE), fracture of lower leg, including ankle (FLLA), fracture of shoulder and upper arm (FSUA), fracture of forearm (FFO), fracture of rib, sternum and thoracic spine (FRSTS) and fracture of lumbar spine and pelvis (FLSP). DVT as the outcome. A two-sample Mendelian randomization (MR) approach was employed to investigate the genetic causal relationship, and a series of sensitivity analyses were conducted.Results: The findings indicated no genetic causal relationship between FFE (p = 0.569, OR 95% CI = 1.001 [0.998-1.003]), FLLA (p = 0.371, OR 95% CI = 0.999 [0.995-1.002]), FSUA (p = 0.871, OR 95% CI = 1.000 [0.998-1.002]), FFO (p = 0.281, OR 95% CI = 1.001 [0.999-1.002]), FRSTS (p = 0.346, OR 95% CI = 0.999 [0.996-1.001]) or FLSP (p = 0.759, OR 95% CI = 1.000 [0.999-1.002]) and DVT. Sensitivity analyses reinforced the robustness.Conclusions: This study indicate that no genetic causal relationship exists between DVT and fracture site, the observed association may be attributable to non-genetic factors.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"155-165"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could targeted gene insertion of factor 9 be a potential durable treatment for Hemophilia B?

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17474086.2025.2459253

Giancarlo Castaman, Mirko Pinotti

引用次数: 0

Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings? tp53突变急性髓性白血病的挑战和新兴治疗策略：仍然令人失望的发现？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1080/17474086.2024.2438241

Matteo Molica

引用次数: 0

Modulation of the endocannabinoid system in chronic conditions: a potential therapeutic intervention yet to be explored in sickle cell disease.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-03-04 DOI: 10.1080/17474086.2025.2471864

Lucas Bibiano de Oliveira Souza, Juliana Paiva Gouvea Sicoli, Sara Teresinha Olalla Saad, Bruno Deltreggia Benites

{"title":"Modulation of the endocannabinoid system in chronic conditions: a potential therapeutic intervention yet to be explored in sickle cell disease.","authors":"Lucas Bibiano de Oliveira Souza, Juliana Paiva Gouvea Sicoli, Sara Teresinha Olalla Saad, Bruno Deltreggia Benites","doi":"10.1080/17474086.2025.2471864","DOIUrl":"10.1080/17474086.2025.2471864","url":null,"abstract":"Introduction: Individuals living with Sickle Cell Disease (SCD) are subject to numerous chronic complications, including disabling chronic pain, often dependent on opioids and with important repercussions on the quality of life. The use of Medicinal Cannabis in this scenario may be a promising strategy for mitigating this impact.Areas covered: This work compiles current knowledge regarding the endocannabinoid system in humans and the role of this system in various organic functions. Articles were retrieved through a comprehensive search of the PubMed NCBI database, covering relevant studies up to 2024. These data bring important speculations on the potential role of the use of medicinal cannabis in modulating SCD chronic complications, and the preliminary results of clinical trials carried out in this condition are discussed.Expert opinion: The search for understanding the role of cannabis-derived products in the management of chronic complications of sickle cell disease could add resources to the serious challenge of dealing with the multiple aspects of the disease faced by patients. They range from the management of chronic pain itself to the risks of opioid dependence, in addition to other difficult scenarios, such as leg ulcers and chronic inflammation and its consequences.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"215-224"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review. 描述用inotuzumab ozogamicin治疗复发/难治性急性淋巴细胞白血病的理想患者：系统文献综述

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-01-14 DOI: 10.1080/17474086.2025.2450223

David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Sabina Chiaretti, Matthias Stelljes

{"title":"Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review.","authors":"David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Sabina Chiaretti, Matthias Stelljes","doi":"10.1080/17474086.2025.2450223","DOIUrl":"10.1080/17474086.2025.2450223","url":null,"abstract":"Introduction: Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes by baseline characteristics for patients with R/R ALL treated with InO to identify which patients may benefit most.Methods: In adherence with PRISMA guidelines, searches were run in Embase and MEDLINE. Inclusion criteria were real-world evidence, observational studies, and phase 2-4 trials. The Cochrane Risk of Bias tool and Newcastle-Ottawa instrument assessed quality.Results: 34 publications were included; 11 described the phase 3 INO-VATE trial. Patients treated with InO who were CD22-positive, in first salvage, and eligible for subsequent hematopoietic stem cell transplant (HSCT) had improved outcomes. Reduced incidence of veno-occlusive disease was observed in patients with normal transaminase levels and bilirubin, no prior liver disease, and who did not receive dual alkylators.Conclusions: The ideal patient for InO treatment has CD22-positive disease (≥20% leukemic blasts), normal liver function, no history of liver disease, is in first salvage, has not previously received HSCT, prefers outpatient treatment, or has high disease burden. Limitations included potentially missing publications that were non-English, not identified in the searches, or available after the date the searches were conducted.Registration: This systematic review was registered on the Prospective Register of Systematic Reviews (PROSPERO), registration number: CRD42022330496.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"91-103"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies. 以tcr为基础的血液恶性肿瘤治疗的临床试验、挑战和变化。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/17474086.2024.2441962

Melinda A Biernacki, Marie Bleakley

{"title":"Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies.","authors":"Melinda A Biernacki, Marie Bleakley","doi":"10.1080/17474086.2024.2441962","DOIUrl":"10.1080/17474086.2024.2441962","url":null,"abstract":"Introduction: T cells engineered to express antigen-specific T cell receptors (TCR; TCR-T) are a promising class of immunotherapeutic for patients with hematologic malignancies. Like chimeric antigen receptor-engineered T cells (CAR-T), TCR-T are cell products with defined specificity and composition. Unlike CAR-T, TCR-T can recognize targets arising both from intracellular and cell surface proteins and leverage the sensitivity of natural TCR signaling machinery. A growing number of TCR-T targeting various antigens in different hematologic malignancies are in early-phase clinical trials, and more are in preclinical development.Areas covered: This review covers results from early-phase TCR-T clinical trials for hematologic malignancies. Challenges in the field are reviewed, including identifying optimal targets, engaging CD4+ help for CD8+ T cells, and overcoming tumor-induced suppression; recent innovations to overcome these challenges are also highlighted.Expert opinion: In the future, TCR-T's promise for hematologic malignancies will be borne out in later-phase clinical trials and approvals for clinical use. Improved antigen discovery methods will help build the toolbox of targets needed for broadly applicable TCR-T. Rationally designed TCR-T modifications including incorporation of accessory receptors and gene editing will enhance TCR-T function. New hybrid receptors combining features of TCR and CAR will enter the clinic.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"21-31"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of erythropoiesis-stimulating agents on malignant neoplasms: FAERS database and Mendelian randomization.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-02-20 DOI: 10.1080/17474086.2025.2468400

Cuilv Liang, Qiaohong Wang, Peihong Wang, Yin Zhang

{"title":"Effect of erythropoiesis-stimulating agents on malignant neoplasms: FAERS database and Mendelian randomization.","authors":"Cuilv Liang, Qiaohong Wang, Peihong Wang, Yin Zhang","doi":"10.1080/17474086.2025.2468400","DOIUrl":"10.1080/17474086.2025.2468400","url":null,"abstract":"Background: The relationship between erythropoiesis-stimulating agents (ESAs) and malignant neoplasms (MNs) has been controversial in previous studies. Our study aimed to explore the correlation between ESAs and MNs.Research design and methods: Drug-target Mendelian randomization (MR) analyses were conducted to evaluate the causal associations of ESAs for 12 classifications of MNs. Meanwhile, a pharmacovigilance study was performed by extracting adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) database to validate and complement our findings. MR analysis revealed negative association of ESAs with MN of ovary (p = 0.047), liposarcoma (p = 0.001), small cell lung cancer (p = 0.017), colorectal cancer (p = 0.004), and brain meningioma (p = 0.004) and revealed positive association of ESAs with MN of bladder (p = 0.001), eye and adnexa (p = 0.012), heart, mediastinum, and pleura (p = 0.032), lip (p = 0.041), larynx (p = 0.015), non-small cell lung cancer (p = 0.009), and malignant melanoma (p = 0.001). Positive signals were found in MN of hematological system, digestive organs, central nervous system, eye and adnexa, head and neck cancer, lung cancer, and mucinous and mucinous cystic tumor in FAERS database (all reporting odds ratio and proportional reporting ratio >1).Conclusion: ESAs were causally correlated with many types of MNs. The use of ESAs in these tumors needs more attention.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"239-247"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

lncRNA GAS 5 rs145204276 as a risk factor for primary immune thrombocytopenia in the Chinese Han population. lncRNA GAS 5 rs145204276是中国汉族人群原发性免疫性血小板减少症的风险因素。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-03-25 DOI: 10.1080/17474086.2025.2483669

Ting Liang, Hong Yi, Huanyu Guo, Yingjie Xie, Jianhua Hu, Yongchun Chen

{"title":"lncRNA GAS 5 rs145204276 as a risk factor for primary immune thrombocytopenia in the Chinese Han population.","authors":"Ting Liang, Hong Yi, Huanyu Guo, Yingjie Xie, Jianhua Hu, Yongchun Chen","doi":"10.1080/17474086.2025.2483669","DOIUrl":"10.1080/17474086.2025.2483669","url":null,"abstract":"Background: Recent studies suggest that long noncoding RNA (lncRNA) GAS 5 plays a crucial role in the pathogenesis of primary immune thrombocytopenia (ITP). Identification of genetic variations affecting GAS 5 expression may provide insights into ITP mechanisms. This study aimed to explore the association between GAS 5 variants rs145204276 andrs55829688 and ITP risk in a Chinese Han population.Research design and methods: The genotypes of rs145204276 and rs55829688 were analyzed in 302 ITP patients and 300 age-matched healthy controls. GAS 5 expression levels were quantified using quantitative real-time PCR (qRT-PCR) in both groups.Results: Significant differences in allele and genotype frequencies of rs145204276 were observed between ITPpatients and healthy controls. Specifically, the deletion allele of rs145204276 was associated with a reduced risk of ITP and higher GAS 5 expression inpatients. However, no significant association was found for rs55829688 in any analysis.Conclusions: The rs145204276polymorphism in GAS 5 is significantly associated with ITP susceptibility and may serve as a potential biomarker for ITP prevention and treatment.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"283-289"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0